Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glucocorticoids commonly used in the posttransplant period have been demonstrated to reduce insulin sensitivity, impair α-cell function, and more recently, impair β-cell function and the incretin effect (1). Liraglutide is an incretin mimetic approved for the treatment of type 2 diabetes. One major concern about the use of liraglutide after transplantation is that it delays gastric emptying, which could potentially affect absorption of coadministered oral medications, such as tacrolimus, which has a narrow therapeutic index (2). This case series is the first to report on the safety of this drug combination in kidney transplant recipients (KTRs). Nonpregnant, adult (≥18 years of age), and clinically stable (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 and not experiencing allograft rejection or two serum creatinine values >30% of each other obtained at least 1 week apart within 4 weeks prior to enrollment) KTRs receiving unchanged tacrolimus doses for ≥4 weeks (goal trough concentration 5–15 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Coadministration of liraglutide and tacrolimus in five kidney transplant recipients resulted in reduced AUC of the latter, but trough levels remained unaltered [26].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The number of subjects was small in one study that was rated poor quality for “sample” [26].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215 · cited 1×
“Evidence for the use of liraglutide in patients with chronic kidney disease is limited (4,5).”
Backgroundvan Raalte, D. H., van Genugten, R. E., Linssen, M. M. L., Ouwens, D. M., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc10-1677 · Cited by 150 · cited 1×
“G lucocorticoids commonly used in the posttransplant period have been demonstrated to reduce insulin sensitivity, impair a-cell function, and more recently, impair b-cell function and the incretin effect (1).”
BackgroundMild Renal Impairment and the Efficacy and Safety of Liraglutide
Davidson, J. A., Brett, J., Falahati, A., & Scott, D. (2010) · Endocrine Practice · doi:10.4158/ep10215.or · Cited by 88
Barraclough, K. A., Isbel, N. M., Kirkpatrick, C. M. J., Lee, K., Taylor, P. J., Johnson, D. W., Campbell, S. B., Leary, D. R., & Staatz, C. E. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03815.x · Cited by 53 · cited 1×
“Tacrolimus area under the curve (AUC)0–12h was measured with a previously validated multiple regression– derived limited sampling strategy (3).”
MethodIncretin-based Therapy in Chronic Kidney Disease
Pinelli, N. R., Moore, C. L., & Tomasello, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.06.003 · Cited by 13
Self-citation
Cited by
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
International consensus on post-transplantation diabetes mellitus
Sharif, A., Chakkera, H. A., de Vries, A. P. J., Eller, K., Guthoff, M., Haller, M. C., Hornum, M., Nordheim, E., Kautzky‐Willer, A., Krebs, M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad258 · Cited by 145
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Thangavelu, T., Lyden, E., & Shivaswamy, V. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00786-1 · Cited by 96
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Fair quality of methodology was considered in studies that enrolled only male subjects (“population” category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13–17, 19, 24].”
BackgroundInfluential
Metadata
- Authors
- Pinelli, N. R., Patel, A., & Salinitri, F. D.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Henry Ford Hospital (US)
- Wayne State University (US)
- Corresponding author
- Patel, Anita
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- e171-e172
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781489
- OpenAlex
- W2048952897
- Cited by
- 75
- References
- 5
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 9 · 2023: 4 · 2022: 3 · 2021: 12 · 2020: 11 · 2019: 3 · 2018: 8 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 1
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, tacrolimus, kidney transplantation, drug-drug interactions, gastric emptying, incretin mimetics, glucocorticoids, type 2 diabetes, drug safety, oral drug absorption
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Humans, Hypoglycemic Agents, Kidney Transplantation, Tacrolimus, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.